BACKGROUND: We recently showed in a pig model of ex vivo lung perfusion (EVLP) that lung edema correlates with glucose consumption. We investigated whether salbutamol, a beta-adrenergic receptor agonist known to upregulate fluid transport in the lung, modulates glucose concentration in the perfusate during EVLP. METHODS: Lungs from domestic pigs underwent normothermic EVLP. At the end of controlled reperfusion, lungs were ventilated and perfused for 60 minutes, then randomized to salbutamol (beta-Agonist) infusion or placebo (Control) for 180 minutes. Functional parameters were assessed. RESULTS: In the beta-Agonist group, glucose concentration decreased over time more than corresponding Control values (analysis of variance [ANOVA], p = 0.05). Mean pulmonary artery pressure (mPAP) was 16 +/- 1 mm Hg in the beta-Agonist group vs 21 +/- 1 mm Hg in the Controls (ANOVA p < 0.05). Baseline mPAP was correlated with the drop of mPAP after the p-agonist infusion (R-2 = 0.856, p < 0.05). Dynamic compliance dropped from 51 10 to 31 6 ml/cm 1420 in the P-Aeonist group and from 60 +/- 4 to 21 +/- 3 ml/cm H2O in the Control group (ANOVA, p < 0.05 beta-agonist vs Control). The A partial pressure of oxygen/fraction of inspired oxygen was 418 +/- 15 and 393 +/- 12 mm Hg in the P-Agonist and Control groups, respectively (t-test p = 0.106). CONCLUSIONS: Glucose concentration in the perfusate was affected by salbutamol. Salbutamol was associated with lower pulmonary pressures and better lung mechanics. These data suggest a possible role for salbutamol as a pharmacologic adjunct during EVLP before transplantation.
β-adrenergic agonist infusion during extracorporeal lung perfusion : effects on glucose concentration in the perfusion fluid and on lung function / F. Valenza, L. Rosso, S. Coppola, S. Froio, J. Colombo, R. Dossi, J. Fumagalli, V. Salice, M. Pizzocri, G. Conte, S. Gatti, L. Santambrogio, L. Gattinoni. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - 31:5(2012 May), pp. 524-530. [10.1016/j.healun.2012.02.001]
β-adrenergic agonist infusion during extracorporeal lung perfusion : effects on glucose concentration in the perfusion fluid and on lung function
F. ValenzaPrimo
;L. RossoSecondo
;S. Coppola;S. Froio;J. Colombo;V. Salice;M. Pizzocri;G. Conte;S. Gatti;L. SantambrogioPenultimo
;L. GattinoniUltimo
2012
Abstract
BACKGROUND: We recently showed in a pig model of ex vivo lung perfusion (EVLP) that lung edema correlates with glucose consumption. We investigated whether salbutamol, a beta-adrenergic receptor agonist known to upregulate fluid transport in the lung, modulates glucose concentration in the perfusate during EVLP. METHODS: Lungs from domestic pigs underwent normothermic EVLP. At the end of controlled reperfusion, lungs were ventilated and perfused for 60 minutes, then randomized to salbutamol (beta-Agonist) infusion or placebo (Control) for 180 minutes. Functional parameters were assessed. RESULTS: In the beta-Agonist group, glucose concentration decreased over time more than corresponding Control values (analysis of variance [ANOVA], p = 0.05). Mean pulmonary artery pressure (mPAP) was 16 +/- 1 mm Hg in the beta-Agonist group vs 21 +/- 1 mm Hg in the Controls (ANOVA p < 0.05). Baseline mPAP was correlated with the drop of mPAP after the p-agonist infusion (R-2 = 0.856, p < 0.05). Dynamic compliance dropped from 51 10 to 31 6 ml/cm 1420 in the P-Aeonist group and from 60 +/- 4 to 21 +/- 3 ml/cm H2O in the Control group (ANOVA, p < 0.05 beta-agonist vs Control). The A partial pressure of oxygen/fraction of inspired oxygen was 418 +/- 15 and 393 +/- 12 mm Hg in the P-Agonist and Control groups, respectively (t-test p = 0.106). CONCLUSIONS: Glucose concentration in the perfusate was affected by salbutamol. Salbutamol was associated with lower pulmonary pressures and better lung mechanics. These data suggest a possible role for salbutamol as a pharmacologic adjunct during EVLP before transplantation.File | Dimensione | Formato | |
---|---|---|---|
2012_Valenza_EVLP B2_JHLT.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
495.58 kB
Formato
Adobe PDF
|
495.58 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.